

# Aurobindo net falls 8% on higher material, staff costs


TRUSHNA UDGIRKAR

Hyderabad

AUROBINDO Pharma has reported a 7.91 per cent drop in its consolidated net profit for the December quarter to Rs 384.43 crore versus Rs 417.49 crore in the corresponding period of the previous financial year. The company's total operating income moved up to Rs 3166.16 crore against Rs 2140.56 crore, growing at 47.9 per cent.

Also, the Ebitda during the quarter moved down by 10.8 per cent on YoY basis as expenses of materials consumption (to net operating income) shot up 6.7 per cent, staff costs grew by 1.7 per cent and other costs too rose by 2.4 per cent.

"We continue to grow our



revenues and maintain profitability despite the absence of any exceptional upside. We have been investing our efforts to further differentiate our product portfolio through initiation of developmental research in highly

complex molecules and novel technology platforms, for a sustainable future," said N Govindarajan, managing director of Aurobindo.

The sales of formulations shot up by 76.2 per cent to Rs 2529.7 crore against Rs 1436.1 crore. But sales from Active Pharmaceutical Ingredients slid by 9.4 per cent to Rs 674.4 crore, against Rs 744.1 crore in the third quarter of the previous financial year.

The company in a statement on Wednesday said that there were no new approvals in the USA during the quarter. Altogether they now have 192 cumulative ANDA approvals including 27 tentative along with 5 withdrawals.

trushnaudgirkar@mydigitalfc.com

Company